// App-Quantinova.ai

2273 : Selection of first-in-human clinical dose range for the tumor-targeted 4-1BB agonist MP0310 (AMG 506) using a pharmacokinetic/pharmacodynamics modeling approach

Researchers

Presenter

  • Alexander Link

Principal Investigators

  • Laurent Juglair

  • Hedi Poulet

  • Guy Lemaillet

  • Christian Reichen

  • Patricia Schildknecht

  • Ivana Tosevski

  • Joanna Robinson

  • Niina Veitonmki

  • Jrg Herbst

  • Keith Dawson

  • Christof Zitt

  • Camila de Almeida

  • Rik de Greef

  • Victor Levitsky

  • Michael T. Stumpp

  • Hong Ji

  • Elmar Vom Baur

Medical Centers

  • Molecular Partners AG, Zurich-Schlieren, Switzerland

  • Certara Strategic Consulting, London, United Kingdom.

  • Certara Strategic Consulting, Oss, Netherlands

Locations

  • Switzerland

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

  • Solid malignancies

Biomarkers

  • Peripheral blood mononuclear cell

  • Cluster of differentiation 8A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • First-In-Human

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved